Literature DB >> 8461276

Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia.

J Addington1, D Addington.   

Abstract

In this study we examined the relationship between premorbid functioning, outcome, cognitive functioning and positive and negative symptoms of schizophrenia. Cognitive functioning and symptoms were examined longitudinally in a sample of 39 subjects with schizophrenia (according to the DSM-III criteria). Subjects were assessed at admission to hospital and six months later during a period of relative remission. Premorbid functioning was significantly associated with negative symptoms but not with positive symptoms at both the acute phase and the remitted phase of the illness. Outcome was also associated with negative symptoms at admission and with both positive and negative symptoms at follow-up. Deficits on cognitive tests of verbal reasoning and concept formation were significantly associated with poor premorbid functioning and outcome.

Entities:  

Mesh:

Year:  1993        PMID: 8461276      PMCID: PMC1188471     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  19 in total

1.  An abbreviated form of the Phillips Rating Scale of Premorbid Adjustment in Schizophrenia.

Authors:  J G Harris
Journal:  J Abnorm Psychol       Date:  1975-04

2.  Premorbid sociosexual functioning and long-term outcome in schizophrenia.

Authors:  R S Keefe; R C Mohs; M F Losonczy; M Davidson; J M Silverman; T B Horvath; K L Davis
Journal:  Am J Psychiatry       Date:  1989-02       Impact factor: 18.112

3.  A multidimensional approach to the genetics of schizophrenia.

Authors:  R H Dworkin; M F Lenzenweger; S O Moldin; G F Skillings; S E Levick
Journal:  Am J Psychiatry       Date:  1988-09       Impact factor: 18.112

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

5.  The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia.

Authors:  J S Strauss; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1974-07

6.  Psychological aspects of focal epilepsy and its neurosurgical management.

Authors:  B Milner
Journal:  Adv Neurol       Date:  1975

7.  Patterns of sex differences in negative symptoms and social functioning consistent with separate dimensions of schizophrenic psychopathology.

Authors:  R H Dworkin
Journal:  Am J Psychiatry       Date:  1990-03       Impact factor: 18.112

8.  Clinical correlates of the deficit syndrome of schizophrenia.

Authors:  R W Buchanan; B Kirkpatrick; D W Heinrichs; W T Carpenter
Journal:  Am J Psychiatry       Date:  1990-03       Impact factor: 18.112

9.  Negative and positive symptoms in schizophrenia and depression: a followup.

Authors:  M F Pogue-Geile; M Harrow
Journal:  Schizophr Bull       Date:  1984       Impact factor: 9.306

10.  Negative symptoms in schizophrenia: their longitudinal course and prognostic importance.

Authors:  M F Pogue-Geile; M Harrow
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

View more
  18 in total

1.  The stress process perspective and adaptation of people with schizophrenia--an exploratory study.

Authors:  Yves Lecomte; Céline Mercier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-02       Impact factor: 4.328

2.  Cognitive decline in schizophrenic patients: relationship to other symptoms.

Authors:  J T Dalby; R Williams; R Dickson; O Yuen
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

3.  Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Authors:  David Walling; Stephen R Marder; John Kane; W Wolfgang Fleischhacker; Richard S E Keefe; David A Hosford; Chris Dvergsten; Anthony C Segreti; Jessica S Beaver; Steven M Toler; John E Jett; Geoffrey C Dunbar
Journal:  Schizophr Bull       Date:  2015-06-12       Impact factor: 9.306

4.  The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions.

Authors:  Moogeh Baharnoori; Cali Bartholomeusz; Aurelie A Boucher; Lisa Buchy; Christopher Chaddock; Bonga Chiliza; Melanie Föcking; Alex Fornito; Juan A Gallego; Hiroaki Hori; Gisele Huf; Gul A Jabbar; Shi Hyun Kang; Yousri El Kissi; Jessica Merchán-Naranjo; Gemma Modinos; Nashaat A M Abdel-Fadeel; Anna-Karin Neubeck; Hsiao Piau Ng; Gabriela Novak; Olasunmbo O Owolabi; Diana P Prata; Naren P Rao; Igor Riecansky; Darryl C Smith; Renan P Souza; Renate Thienel; Hanan D Trotman; Hiroyuki Uchida; Kristen A Woodberry; Anne O'Shea; Lynn E DeLisi
Journal:  Schizophr Res       Date:  2010-10-08       Impact factor: 4.939

5.  Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder.

Authors:  Alex Hofer; Maria A Rettenbacher; Christian G Widschwendter; Georg Kemmler; Martina Hummer; W Wolfgang Fleischhacker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-29       Impact factor: 5.270

6.  Cognitive impairment from early to middle adulthood in patients with affective and nonaffective psychotic disorders.

Authors:  Josephine Mollon; Samuel R Mathias; Emma E M Knowles; Amanda Rodrigue; Marinka M G Koenis; Godfrey D Pearlson; Abraham Reichenberg; Jennifer Barrett; Dominique Denbow; Katrina Aberizk; Molly Zatony; Russell A Poldrack; John Blangero; David C Glahn
Journal:  Psychol Med       Date:  2019-01-04       Impact factor: 7.723

7.  CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.

Authors:  Joelle Choueiry; Crystal M Blais; Dhrasti Shah; Dylan Smith; Derek Fisher; Vadim Illivitsky; Verner Knott
Journal:  Psychopharmacology (Berl)       Date:  2020-08-27       Impact factor: 4.530

8.  Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.

Authors:  Fernando Cañas; Víctor Pérez-Solá; Silvia Díaz; Javier Rejas
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  Altered spatial profile of distraction in people with schizophrenia.

Authors:  Carly J Leonard; Benjamin M Robinson; Britta Hahn; Steven J Luck; James M Gold
Journal:  J Abnorm Psychol       Date:  2017-11

10.  Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.

Authors:  Ronald G Robinson; Sean M Smith; Scott E Wolkenberg; Monika Kandebo; Lihang Yao; Christopher R Gibson; Scott T Harrison; Stacey Polsky-Fisher; James C Barrow; Peter J Manley; James J Mulhearn; Kausik K Nanda; Jeffrey W Schubert; B Wesley Trotter; Zhijian Zhao; John M Sanders; Robert F Smith; Debra McLoughlin; Sujata Sharma; Dawn L Hall; Tiffany L Walker; Jennifer L Kershner; Neetesh Bhandari; Pete H Hutson; Nancy A Sachs
Journal:  ACS Chem Neurosci       Date:  2011-11-14       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.